Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3049% below fair value
$149.40−7.10 (-4.54%)
Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –
Alnylam Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Alnylam Pharmaceuticals's total assets was $7.99B at Sep 30, 2026. For fiscal 2025 it was $4.97B, up 17.1% from the year before. Over ten years it grew 13.6% a year on average. The highest annual figure on record is $4.97B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.97B | +17.1% |
| FY2024 | Dec 31, 2024 | $4.24B | +10.7% |
| FY2023 | Dec 31, 2023 | $3.83B | +8.0% |
| FY2022 | Dec 31, 2022 | $3.55B | -2.7% |
| FY2021 | Dec 31, 2021 | $3.64B | +6.9% |
| FY2020 | Dec 31, 2020 | $3.41B | +42.2% |
| FY2019 | Dec 31, 2019 | $2.40B | +52.1% |
| FY2018 | Dec 31, 2018 | $1.57B | -21.1% |
| FY2017 | Dec 31, 2017 | $1.99B | +58.0% |
| FY2016 | Dec 31, 2016 | $1.26B | -8.9% |
| FY2015 | Dec 31, 2015 | $1.39B | +28.4% |
| FY2014 | Dec 31, 2014 | $1.08B | +156.7% |
| FY2013 | Dec 31, 2013 | $420.53M | +46.3% |
| FY2012 | Dec 31, 2012 | $287.52M | +2.0% |
| FY2011 | Dec 31, 2011 | $281.92M | -28.3% |
| FY2010 | Dec 31, 2010 | $393.27M | -18.3% |
| FY2009 | Dec 31, 2009 | $481.39M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $7.99B | +64.8% |
| Q2 FY2026 | Jun 30, 2026 | $5.56B | +21.7% |
| Q1 FY2026 | Mar 31, 2026 | $5.13B | +21.7% |
| Q4 FY2025 | Dec 31, 2025 | $4.97B | +17.1% |
| Q3 FY2025 | Sep 30, 2025 | $4.85B | +15.4% |
| Q2 FY2025 | Jun 30, 2025 | $4.57B | +13.9% |
| Q1 FY2025 | Mar 31, 2025 | $4.21B | +10.2% |
| Q4 FY2024 | Dec 31, 2024 | $4.24B | +10.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.21B | +9.5% |
| Q2 FY2024 | Jun 30, 2024 | $4.01B | +17.8% |
| Q1 FY2024 | Mar 31, 2024 | $3.82B | +12.7% |
| Q4 FY2023 | Dec 31, 2023 | $3.83B | +8.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.84B | +8.6% |
| Q2 FY2023 | Jun 30, 2023 | $3.40B | +2.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.39B | -1.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.55B | -2.7% |
| Q3 FY2022 | Sep 30, 2022 | $3.54B | +1.8% |
| Q2 FY2022 | Jun 30, 2022 | $3.33B | -5.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.43B | +5.5% |
| Q4 FY2021 | Dec 31, 2021 | $3.64B | +6.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.47B | +5.0% |
| Q2 FY2021 | Jun 30, 2021 | $3.51B | +4.0% |
| Q1 FY2021 | Mar 31, 2021 | $3.26B | +42.8% |
| Q4 FY2020 | Dec 31, 2020 | $3.41B | +42.2% |
| Q3 FY2020 | Sep 30, 2020 | $3.31B | +30.1% |
| Q2 FY2020 | Jun 30, 2020 | $3.37B | +24.2% |
| Q1 FY2020 | Mar 31, 2020 | $2.28B | +13.2% |
| Q4 FY2019 | Dec 31, 2019 | $2.40B | +52.1% |
| Q3 FY2019 | Sep 30, 2019 | $2.54B | +51.7% |
| Q2 FY2019 | Jun 30, 2019 | $2.72B | +51.8% |
| Q1 FY2019 | Mar 31, 2019 | $2.01B | +4.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.57B | -21.1% |
| Q3 FY2018 | Sep 30, 2018 | $1.68B | +23.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.79B | +24.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.92B | +69.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.99B | +58.0% |
| Q3 FY2017 | Sep 30, 2017 | $1.36B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.43B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.13B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.26B | – |
See a number that looks wrong?